Nuria Pleitez, MD
General Practice · Covina, CANPI 1942361332
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 30.7% of the total. Reporting peaked in 2019 at $1,241 and has fallen 66.0% since, to $422 in 2025. Among general practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $75.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$820
- GSK$748
- Amgen$370
- Abbott$243
- Lilly USA, LLC$228
- plus $374 from 5 others
Across 17 payments — averaging $4219.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$36K
- Chiesi USA, Inc.$18K
- Pfizer$17K
- Cipla USA Inc.$2K
What the payments were for
- Food & beverage$4,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,231 |
| Novo Nordisk | 11 | $820 |
| GSK | 9 | $748 |
| Amgen | 3 | $370 |
| Abbott | 2 | $243 |
| Lilly USA, LLC | 5 | $228 |
| Phadia US Inc. | 3 | $177 |
| Boehringer Ingelheim | 2 | $63 |
| Merck | 3 | $58 |
| Exact Sciences | 3 | $58 |
| Astellas Pharma US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$969
- Ozempic$341
- AIRSUPRA$245
- AREXVY$244
- SHINGRIX$238
- Xultophy 100/3.6$135
- RYBELSUS$125
- Prolia$125
- FreeStyle Libre Pro$124
- EVENITY$123
- BEXSERO$122
- Repatha$122
- Proclaim Family of SCS IPGs$119
- TRULICITY$111
How this compares
$4,014 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 45 | $55,344 |
| FarxigaDapagliflozin Propanediol | 27 | $33,012 |
| JardianceEmpagliflozin | 21 | $29,795 |
| EliquisApixaban | 19 | $21,287 |
| OzempicSemaglutide | 23 | $20,543 |
| Diclofenac Sodium | 50 | $8,974 |
| Rosuvastatin Calcium | 198 | $3,404 |
| Albuterol Sulfate | 23 | $2,463 |
| Ibandronate Sodium | 67 | $2,435 |
| Losartan Potassium | 186 | $2,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,000 |
| Levothyroxine Sodium | 150 | $1,391 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,372 |
| Fenofibrate | 33 | $1,186 |
| Amlodipine Besylate | 209 | $1,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $58 | $55,34445 claims |
| AstraZenecaFarxiga | $1,231 | $33,01227 claims |
| Boehringer IngelheimJardiance | $63 | $29,79521 claims |
| Novo NordiskOzempic | $820 | $20,54323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Covina
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.